GlaxoSmithKline News and Research

RSS

Metabolon, GSK sign research collaboration agreement

Metabolon, Inc., a leading diagnostics and research services company offering metabolomics research platforms, has entered into a collaboration with GlaxoSmithKline to provide metabolomic profiling services and to collaborate on other research projects leveraging Metabolon's leading DiscoveryHD4 platform.

14 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet.

From Sanofi 7 May 2014

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GlaxoSmithKline plc and Theravance, Inc. today announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies in the US.

28 Apr 2014

FDA grants marketing approval to GlaxoSmithKline's diabetes drug based on Novozymes' Veltis technology

The US Food and Drug Administration has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week.

25 Apr 2014

Targeting B cells may help reduce disease activity for people with multiple sclerosis

A new study suggests that targeting B cells, which are a type of white blood cell in the immune system, may be associated with reduced disease activity for people with multiple sclerosis (MS).

25 Apr 2014

Sales of hepatitis drug shatter records

Record sales of the pricey new drug, Sovaldi, pushed first-quarter earnings of Gilead Sciences beyond expectations. Meanwhile, Novartis' recently announced deals with GlaxoSmithKline and Eli Lilly show manufacturers' swing towards specialization, reports The Wall Street Journal.

25 Apr 2014

Novartis to buy Glaxosmithkline's oncology unit

The deal, worth billions, will also see Novartis sell its vaccines unit to Glaxo and partner with Glaxo on their consumer divisions. Novartis also said it will sell its animal health division to Eli Lily.

23 Apr 2014

First Edition: April 22, 2014

Today's early morning highlights from the major news organizations, including marketplace news about the Novartis purchase of GlaxoSmithKline's oncology unit for $14.5 billion.

22 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

16 Apr 2014

Study shows 25 percent of Colorado foster kids on psychotropic drugs

The rate is 12 times greater than for other children on government insurance, a new study in Colorado finds.

15 Apr 2014

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza.

11 Apr 2014

FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States.

9 Apr 2014

MD Anderson forms research alliance with GSK to identify new therapeutic approaches to combat cancer

The University of Texas MD Anderson Cancer Center announced today it formed a research alliance with GlaxoSmithKline (GSK), a global leader in pharmaceutical development, to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer.

9 Apr 2014

Proprietary Novozymes technology used in GlaxoSmithKline’s new diabetes treatment

Novozymes Biopharma DK A/S, a subsidiary of Novozymes A/S, a world leader in bioinnovation, has announced that its albumin-based VELTIS half-life extension technology is being used by GlaxoSmithKline in the recently authorized Eperzan (albiglutide) for the treatment of type 2 diabetes in Europe.

1 Apr 2014

New -7 million centre to lead research in manufacturing advanced chemical products

A new -7 million centre at the University of Leeds will lead UK research in manufacturing advanced chemical products. The Centre for Doctoral Training (CDT) in Complex Particulate Products and Processes will fund 50 new research students in a field that has been targeted by the Government as a key growth area for the UK economy.

29 Mar 2014

Two doses of HPV-16/18 AS04-adjuvanted vaccine Cervarix non-inferior to three-doses

A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.

29 Mar 2014

Study: Just 1 in 5 eligible for premium subsidies seek coverage

Sign-up rates varied greatly by state, with more than half of the $10 billion allotted so far going to consumers in California, Florida, North Carolina, Texas and New York, according to the Kaiser Family Foundation study. Meanwhile, the Treasury Department allows battered spouses filing separate income taxes to claim subsidies. Also, Merck and GlaxoSmithKline hold off on helping Obamacare enrollees with copays.

28 Mar 2014

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

GlaxoSmithKline News and Research

Metabolon, GSK sign research collaboration agreement

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

FDA grants marketing approval to GlaxoSmithKline's diabetes drug based on Novozymes' Veltis technology

Targeting B cells may help reduce disease activity for people with multiple sclerosis

Sales of hepatitis drug shatter records

Novartis to buy Glaxosmithkline's oncology unit

First Edition: April 22, 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

Study shows 25 percent of Colorado foster kids on psychotropic drugs

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

MD Anderson forms research alliance with GSK to identify new therapeutic approaches to combat cancer

Proprietary Novozymes technology used in GlaxoSmithKline’s new diabetes treatment

New -7 million centre to lead research in manufacturing advanced chemical products

Two doses of HPV-16/18 AS04-adjuvanted vaccine Cervarix non-inferior to three-doses

Study: Just 1 in 5 eligible for premium subsidies seek coverage

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News